These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

155 related articles for article (PubMed ID: 23291117)

  • 1. Linear and cyclic glycopeptide as HIV protease inhibitors.
    Pawar SA; Jabgunde AM; Maguire GE; Kruger HG; Sayed Y; Soliman ME; Dhavale DD; Govender T
    Eur J Med Chem; 2013 Feb; 60():144-54. PubMed ID: 23291117
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Synthesis and molecular modelling studies of novel carbapeptide analogs for inhibition of HIV-1 protease.
    Pawar SA; Jabgunde AM; Govender P; Maguire GE; Kruger HG; Parboosing R; Soliman ME; Sayed Y; Dhavale DD; Govender T
    Eur J Med Chem; 2012 Jul; 53():13-21. PubMed ID: 22542107
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nonpeptide cyclic cyanoguanidines as HIV-1 protease inhibitors: synthesis, structure-activity relationships, and X-ray crystal structure studies.
    Jadhav PK; Woerner FJ; Lam PY; Hodge CN; Eyermann CJ; Man HW; Daneker WF; Bacheler LT; Rayner MM; Meek JL; Erickson-Viitanen S; Jackson DA; Calabrese JC; Schadt M; Chang CH
    J Med Chem; 1998 Apr; 41(9):1446-55. PubMed ID: 9554878
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Synthesis, screening and computational investigation of pentacycloundecane-peptoids as potent CSA-HIV PR inhibitors.
    Makatini MM; Petzold K; Arvidsson PI; Honarparvar B; Govender T; Maguire GE; Parboosing R; Sayed Y; Soliman ME; Kruger HG
    Eur J Med Chem; 2012 Nov; 57():459-67. PubMed ID: 22867528
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Design and synthesis of highly potent HIV-1 protease inhibitors with novel isosorbide-derived P2 ligands.
    Qiu X; Zhao GD; Tang LQ; Liu ZP
    Bioorg Med Chem Lett; 2014 Jun; 24(11):2465-8. PubMed ID: 24767846
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Synthesis and biological evaluation of new simple indolic non peptidic HIV Protease inhibitors: the effect of different substitution patterns.
    Bonini C; Chiummiento L; Di Blasio N; Funicello M; Lupattelli P; Tramutola F; Berti F; Ostric A; Miertus S; Frecer V; Kong DX
    Bioorg Med Chem; 2014 Sep; 22(17):4792-802. PubMed ID: 25074848
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Identification of constrained peptidomimetic chemotypes as HIV protease inhibitors.
    Calugi C; Guarna A; Trabocchi A
    Eur J Med Chem; 2014 Sep; 84():444-53. PubMed ID: 25042102
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design and synthesis of novel P2 substituents in diol-based HIV protease inhibitors.
    Adrian Meredith J; Wallberg H; Vrang L; Oscarson S; Parkes K; Hallberg A; Samuelsson B
    Eur J Med Chem; 2010 Jan; 45(1):160-70. PubMed ID: 19926360
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pentacycloundecane derived hydroxy acid peptides: a new class of irreversible non-scissile ether bridged type isoster as potential HIV-1 wild type C-SA protease inhibitors.
    Karpoormath R; Sayed Y; Govender P; Govender T; Kruger HG; Soliman MES; Maguire GEM
    Bioorg Chem; 2012 Feb; 40(1):19-29. PubMed ID: 21982718
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Structural analysis of lead fullerene-based inhibitor bound to human immunodeficiency virus type 1 protease in solution from molecular dynamics simulations.
    Lee VS; Nimmanpipug P; Aruksakunwong O; Promsri S; Sompornpisut P; Hannongbua S
    J Mol Graph Model; 2007 Sep; 26(2):558-70. PubMed ID: 17468026
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Synthesis, 2D-NMR and molecular modelling studies of pentacycloundecane lactam-peptides and peptoids as potential HIV-1 wild type C-SA protease inhibitors.
    Makatini MM; Petzold K; Alves CN; Arvidsson PI; Honarparvar B; Govender P; Govender T; Kruger HG; Sayed Y; JerônimoLameira ; Maguire GE; Soliman ME
    J Enzyme Inhib Med Chem; 2013 Feb; 28(1):78-88. PubMed ID: 22339087
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Small-molecule dimerization inhibitors of wild-type and mutant HIV protease: a focused library approach.
    Shultz MD; Ham YW; Lee SG; Davis DA; Brown C; Chmielewski J
    J Am Chem Soc; 2004 Aug; 126(32):9886-7. PubMed ID: 15303839
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Structure-based design: synthesis and biological evaluation of a series of novel cycloamide-derived HIV-1 protease inhibitors.
    Ghosh AK; Swanson LM; Cho H; Leshchenko S; Hussain KA; Kay S; Walters DE; Koh Y; Mitsuya H
    J Med Chem; 2005 May; 48(10):3576-85. PubMed ID: 15887965
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Synthesis and biological evaluation of novel HIV-1 protease inhibitors using tertiary amine as P2-ligands.
    Yang ZH; Bai XG; Zhou L; Wang JX; Liu HT; Wang YC
    Bioorg Med Chem Lett; 2015 May; 25(9):1880-3. PubMed ID: 25838144
    [TBL] [Abstract][Full Text] [Related]  

  • 15. HIV-1 protease inhibitors: synthesis and biological evaluation of glycopeptidemimetics.
    Ghosh AK; McKee SP; Sanders WM; Darke PL; Zugay JA; Emini EA; Schleif WA; Quintero JC; Huff JR; Anderson PS
    Drug Des Discov; 1993; 10(1):77-88. PubMed ID: 8399995
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Structural and dynamical properties of different protonated states of mutant HIV-1 protease complexed with the saquinavir inhibitor studied by molecular dynamics simulations.
    Aruksakunwong O; Wittayanarakul K; Sompornpisut P; Sanghiran V; Parasuk V; Hannongbua S
    J Mol Graph Model; 2006 Nov; 25(3):324-32. PubMed ID: 16504560
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Synthesis and biological evaluation of novel amprenavir-based P1-substituted bi-aryl derivatives as ultra-potent HIV-1 protease inhibitors.
    Yan J; Huang N; Li S; Yang LM; Xing W; Zheng YT; Hu Y
    Bioorg Med Chem Lett; 2012 Mar; 22(5):1976-9. PubMed ID: 22306123
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Novel arylsulfonamides possessing sub-picomolar HIV protease activities and potent anti-HIV activity against wild-type and drug-resistant viral strains.
    Miller JF; Furfine ES; Hanlon MH; Hazen RJ; Ray JA; Robinson L; Samano V; Spaltenstein A
    Bioorg Med Chem Lett; 2004 Feb; 14(4):959-63. PubMed ID: 15013001
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Synthesis of P1'-functionalized macrocyclic transition-state mimicking HIV-1 protease inhibitors encompassing a tertiary alcohol.
    De Rosa M; Unge J; Motwani HV; Rosenquist Å; Vrang L; Wallberg H; Larhed M
    J Med Chem; 2014 Aug; 57(15):6444-57. PubMed ID: 25054811
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Enhanced replication of R5 HIV-1 isolates in vitro by a small-molecule reagent targeting HIV-1 protease.
    Wardle NJ; Hudson HR; Matthews RW; Nunn CM; Vella C; Bligh SW
    ChemMedChem; 2013 May; 8(5):719-21. PubMed ID: 23509042
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.